1 Examining the possible causal relationship between Lung Function, COPD

2 and Alzheimer's Disease. A Mendelian Randomization Study

Daniel H Higbee^{1,2}, Raquel Granell², Esther Walton^{2,3}, Roxanna Korologou-Linden², George
 Davey Smith², James W Dodd^{1,2}

- 5 1 Academic Respiratory Unit, North Bristol NHS Foundation Trust, Bristol, UK
- 6 2 MRC Integrative Epidemiology Unit (IEU), University of Bristol, UK.
- 7 3 Department of Psychology, University of Bath, Bath, UK
- 8 Corresponding Author: Dr James Dodd
- 9 Orcid 0000-0003-4805-5759
- 10 James.dodd@bristol.ac.uk
- 11 Tel +44117 4142012
- 12 Fax +44117 4149496
- 13
- 14 All authors made substantial contributions to analysis, drafting and final approval of the
- 15 paper. DHH, JWD, RG and GDS were involved in the conception.
- 16 Funding: This work was supported by the Medical Research Council and the University of
- 17 Bristol (MC_UU_12013/1, MC_UU_12013/6). MRC CARP Fellowship
- 18 Conflicts of interest: Authors have no conflicts of interest to declare

19 Abstract

20 Rationale: Large retrospective case-control studies have reported an association between

21 COPD, reduced lung function and an increased risk of Alzheimer's disease. However, it

22 remains unclear if these diseases are causally linked, or due to shared risk factors.

23 Conventional observational epidemiology suffers from unmeasured confounding and reverse

24 causation. Additional analyses addressing causality are required.

Objectives: To examine a causal relationship between COPD, lung function and Alzheimer'sdisease.

27 Methods: Using two-sample Mendelian randomization, we utilised single nucleotide

28 polymorphisms (SNPs) identified in a genome wide association study (GWAS) for lung

29 function as instrumental variables (exposure). Additionally, we used SNPs discovered in a

30 GWAS for COPD in those with moderate to very severe obstruction. The effect of these

31 SNPs on Alzheimer's disease (outcome) were taken from a GWAS based on a sample of

32 24,807 patients and 55,058 controls.

33 Results: We found minimal evidence for an effect of either lung function (odds ratio

34 [OR]:1.02 per SD; 95% confidence interval [CI]: 0.91-1.13; p-value 0.68). or liability for

35 COPD on Alzheimer's disease (OR: 0.97 per SD; 95% CI: 0.92 – 1.03; p-value 0.40).

Conclusion: Neither reduced lung function nor liability COPD are likely to be causally
associated with an increased risk of Alzheimer's, any observed association is likely due to
unmeasured confounding. Scientific attention and health prevention policy may be better
focused on overlapping risk factors, rather than attempts to reduce risk of Alzheimer's
disease by targeting impaired lung function or COPD directly.

41 Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a disease of multi-morbidity⁽¹⁾. In COPD 42 the presence of multi-morbidity is associated with higher mortality, worse quality of life and 43 increased healthcare utilisation ^(2, 3). Impaired lung function measures such as Forced 44 Expiratory Volume in one second (FEV₁) and Forced Expiratory Volume (FVC) have been 45 found to be strongly associated with multi-morbidity.⁽⁴⁾ However, it remains unclear if these 46 multi-morbidities are causally linked to lung function and disease, for example through a 47 proposed inflammatory overspill, or if they are due to shared risk factors, such as smoking ⁽⁵⁾. 48 49 Therapeutic targets may be identified if specific causal mechanisms could be established. 50 Cognitive impairment is a common co-morbidity in COPD, with reported prevalence ranging 51 from 10-61% and around 25% of older adults with dementia also have COPD⁽⁶⁾. Cognitive 52 impairment in COPD is associated with greater disability⁽⁷⁾, poorer medication compliance,⁽⁸⁾ 53 and risk of exacerbation and mortality⁽⁷⁾. Poor pulmonary function in early life has been 54 associated with increased odds of dementia later in life, even after adjustment for smoking.⁽⁹⁾ 55 56 Alzheimer's disease (AD) is the most common type of dementia⁽¹⁰⁾, its association with 57 COPD is less well defined than general cognitive ability, but reports of a potential link 58 between COPD and AD was first described nearly 30 years ago⁽¹¹⁾. Large retrospective 59 60 observational case-control cohorts have reported increased risk of AD in patients with both COPD and reduced lung function^(12, 13). For example, Lutsey et al reviewed hospitalisation 61 codes⁽¹³⁾ in the Atherosclerosis Risk In Communities Study for AD-related outcomes and 62 reported that an Odds Ratio of 1.24 for AD-type dementia or mild cognitive impairment 63 (MCI) in patients with COPD and OR 1.79 for those with a restrictive impairment compared 64

to controls. If the lung function and COPD have a causal effect on risk of Alzheimer'sdisease, then they could be modifiable risk factors.

67

Mendelian Randomization (MR) is an established genetic epidemiological method which can 68 overcome problems of unmeasured confounders and reverse causation, typical of 69 conventional observational epidemiology⁽¹⁴⁾. MR allows causal inference through the use of 70 genetic variants as proxies for non-genetic (modifiable) risk factors or health outcomes⁽¹⁴⁾. 71 MR uses genetic data, e.g. single nucleotide polymorphisms (SNPs) that are associated with 72 73 an exposure (in this case diagnosis of COPD or lung function), and uses them as instrumental variables (IV) to assess the causal effect of the exposure on the outcome of interest (in this 74 case Alzheimer's disease)⁽¹⁵⁾. 75 76 MR has multiple advantages. Genetic variants are randomly allocated at birth which can be exploited to simulate randomisation⁽¹⁵⁾. They are not influenced by behavioural or 77 environmental factors minimizing reverse causality (where the outcome, or early stages of the 78 disease process that leads to the outcome, influences the exposure)⁽²⁰⁾. Additionally, the 79 effects are equivalent to lifetime differences, reducing issues relating to transient fluctuations. 80 Our objective was to use MR to investigate if there is any evidence of a causal effect between 81 the exposures, lung function and liability to COPD and the outcome, Alzheimer's disease. 82

83 Methods

84 <u>Lung Function</u>

85 We used data from Shrine et al. the largest currently available lung function GWAS,

- 86 n=400,102 ⁽¹⁶⁾ which reported 279 genome wide significant SNPs ($p < 5 \times 10^{-9}$). Lung function
- 87 measurements used were Forced Expiratory Volume in 1 second (FEV₁), Forced Vital
- 88 Capacity (FVC), FEV₁/FVC ratio and Peak Expiratory Flow (PEF). A weighted risk score,
- 89 was associated with risk of COPD ($p=6.64 \times 10^{-63}$), with an Odds ratio of 1.55 for each
- 90 standard deviation of the risk score ^(16, 17). Further details of the study population can be found
- 91 in the supplementary information and the reference $^{(16)}$.
- 92 <u>COPD</u>

We used 82 SNPs associated with COPD, as identified in Sarkonsakaplat et al. case control GWAS⁽¹⁸⁾, n = 35,735 cases and 222,076 controls discovered in meta-analysis of 25 studies. COPD was defined by Global Initiative for Chronic Obstructive Lung Disease criteria; FEV₁/FVC <0.7 and FEV₁ <80% predicted. Further details of study population can be found in the supplementary information and the reference.⁽¹⁸⁾

80% and 77% of the Shrine et al and Sarkonsakaplat et al GWAS sample respectively were
from the UKBiobank ⁽¹⁹⁾. In brief the UK Biobank is a large prospective cohort study where
>500,000 participants were recruited from 2006 – 2010 in the United Kingdom (54% female).
Pre-bronchodilation lung function testing was performed by trained healthcare staff.

102 <u>Alzheimer's disease</u>

- 103 We used data from a meta-analysis of the International Genomics of Alzheimer's disease
- 104 (IGAP) consortium⁽²⁰⁾, Alzheimer's Disease Sequencing Project (ADSP) ⁽²¹⁾, and Psychiatric
- 105 Genomics Consortium (PGC) ⁽²²⁾ totalling 24,807 Alzheimer's disease cases and 55,058
- 106 controls ⁽²³⁾. All cases had clinical diagnoses of Alzheimer's disease. Some participants of the
- 107 ADSP cohort were previously also included in IGAP, so ADSP individuals that were

duplicates based on the comparison of individual level genetic data between IGAP and ADSPwere excluded.

110 There was no sample overlap between the exposure and outcome samples. All participants111 were of European ancestry.

112 <u>Statistical Analysis</u>

Statistical analysis was done using R Studio version 3.5.1. and the MRCIEU/TwoSampleMR
R package ⁽²⁴⁾.

115

116 For exposure traits r^2 was estimated for each genetic instrument and used to determine the

117 Cragg-Donald overall F-statistic.⁽²⁵⁾ The higher the F-statistic the lower the chance of weak

instrument bias.⁽²⁵⁾ For all exposures SNPs LD-clumping was performed using European

reference population (kb = 10000, r^2 0.001). Palindromic SNPs (i.e. A/T and C/G SNPs) with

120 intermediate allele frequencies were excluded. The remaining SNPs were harmonised⁽²⁶⁾.

121 Steiger filtering⁽²⁷⁾ was performed to remove variants that caused more variance of the

122 outcome than the exposure, see online supplement for more details.

123 <u>Main Mendelian Randomization Analysis</u>

124 Inverse Variance Weighting (IVW) was used for main effect estimate. This is a weighted

125 regression of SNP-outcome on SNP-exposure associations combined where the y intercept is

126 constrained to zero.

127 Assumption and Sensitivity Analysis

128 MR assumptions and further details of tests used, are detailed in the online appendix. To

account for the possibility of horizontal pleiotropy (IVs influence exposure and outcome

through independent pathways), we performed MR Egger. To minimise the effect of

unbalanced instruments on an overall estimate of the mean, weighted median and mode MR

132 methods were performed. To assess for horizontal pleiotropy a funnel plot was made by

plotting the effect against its precision (beta against standard error). To ensure the results
were not due to outliers with a large effect, a leave-one-out analysis was performed by reestimating the total effect after sequentially excluding one SNP at a time and a single-SNP
analysis, where the effect of each SNP was individually assessed via IVW analysis and
represented in a forest plot.
Heterogeneity (the variability in causal estimates obtained for each SNP) is an indication of

139 potential violation of assumptions. This was calculated and assessed with a Q statistic.

140 **Results**

F-statistic for lung function GWAS⁽¹⁶⁾ exposures were; All traits=111, FEV₁=69, FVC=70,
FEV₁/FVC=148, making weak instrument bias unlikely. After clumping, extracting SNPs
from outcome GWAS, Steiger filtering and removal of palindromic SNPs, 131 SNPs were
available for analysis. See flow charts in supplementary information for detailed analysis
pathway.

146

We found minimal evidence for a causal effect of lung function (all traits) on Alzheimer's 147 148 disease, (IVW odds ratio [OR]:1.02 per SD; 95% CI: 0.91-1.13; p-value 0.68). This result was further confirmed in a sensitivity analysis using both weighted median (OR:1.01 per SD; 149 95% CI:0.86-1.19, p value = 0.81), and weighted mode MR (OR 0.99 per SD;95% CI 0.78-150 1.19), p-value = 0.81). risk of AD. The MR-Egger causal estimation produced similar results 151 with an OR 1.05 per SD (95% CI 0.79-1.34; p-value 0.71). The confidence interval of the 152 MR-Egger is wider than that of IVW, consistent with the lower statistical power of this test. 153 154 Figure 1 plots each individual SNP-exposure effect against SNP-outcome with the coloured 155 lines representing each statistical test. Increasing lung function (exposure) does not have a 156 consistent effect on Alzheimer's disease (outcome). 157 158 159 Table 1 shows that these results were consistent when analysing lung function traits FEV₁, FVC, and FEV₁/FVC individually with little evidence of a causal association on Alzheimer's 160

161 disease with confidence intervals crossing 1 for all statistical tests.

162

163

	Lung Function Trait (Exposure)				
		FEV ₁ , FVC, FEV ₁ /FVC, PEF	FEV_1	FVC	FEV ₁ /FVC
No. SNPs		131	42	46	73
used		1.02	1.04	1.00	0.00
	OR per SD	1.02	1.04	1.08	0.99
IVW	(95% CI)	(0.91 - 1.13)	(0.82 - 1.32)	(0.85 - 1.37)	(0.88 - 1.13)
	p-Value	0.68	0.73	0.51	0.97
	Q_p-value*	0.26	0.30	0.19	0.71
Waightad	OR per SD	1.01	1.15	1.14	0.95
Median	(95% CI)	(0.86 - 1.19)	(0.82 - 1.61)	(0.83 - 1.58)	(0.79 - 1.15)
	p-Value	0.81	0.39	0.39	0.62
Weighted Mode	OR per SD	0.99	1.07	1.04	0.97
	(95% CI)	(0.78 - 1.26)	(0.60 - 1.90)	(0.61 - 1.78)	(0.74 - 1.26)
	p-Value	0.97	0.80	0.86	0.84
MR- Egger	OR per SD	1.05	1.22	0.97	0.95
	(95% CI)	(0.79 - 1.34)	(0.57 - 2.59)	(0.36 - 2.62)	(0.69 – 1.31)
	p-Value	0.71	0.59	0.96	0.77

166

*A test for heterogenity. If this was <0.05 it would suggest heterogenity

168 OR – Odd ratio; CI – Confidence Interval; IVW – Inverse Variance Weighting

169

We used single-SNP analyses to determine the effect of each lung function SNP on the odds
of Alzheimer's disease (Figure 2). The SNP rs2070600, may be an outlier due to its
comparatively large effect on both lung function and AD. Polymorphisms in this SNP have
been described as having a weak effect on Alzheimer's disease risk.⁽²⁸⁾ However, despite
excluding this SNP from the analysis the results were similar (e.g. see leave-one-out analysis
in Figure 3).

177 Each SNP beta was plotted against its inverse standard error (**Figure 4**) producing a funnel

shape indicating no heterogeneity. In addition to these visual tests, we found little evidence of

179 heterogeneity using a Q statistic when lung function traits were combined or assessed

180	individually (Table 1. Q_p value >0.51). MR-Egger intercept was <0.001, visually displayed
181	in Figure 1, indicating there was no unbalanced horizontal pleiotropy.

182

183 Using the COPD GWAS⁽¹⁸⁾ gave an F-statistic of 52. After clumping, extracting SNPs

184 from outcome GWAS, Steiger filtering and removal of palindromic SNPs, 53 SNPs for

185 liability to COPD were available for analysis in the Alzheimer's outcome GWAS. Please

see flow chart in supplementary information for details. Results are displayed in **Table 2**.

187 Table 2. Two-sample MR results of COPD⁽¹⁸⁾ on Alzheimer's disease⁽²⁹⁾

	COPD	
No. SNPs		53
used		55
	OR per SD (95% CI)	0.97 (0.92 - 1.03)
IVW	p-Value	0.40
	Q_p-value	0.57
Weighted	OR per SD (95% CI)	0.97 (0.90 - 1.05)
Median	p-Value	0.52
Weighted	OR per SD (95% CI)	0.96(0.86 - 1.08)
Mode	p-Value	0.56
MD Eggor	OR per SD (95% CI)	1.10 (0.93 - 1.31)
MR-Egger	p-Value	0.23

188

189 OR – Odd ratio; CI – Confidence Interval; IVW – Inverse Variance Weighting

190

191 We found minimal evidence for an effect of liability to COPD on risk of Alzheimer's disease

192 (IVW OR: 0.97 per SD; 95% CI: 0.92 - 1.03; p-value 0.40). This result was further

193 confirmed in our sensitivity analysis using both weighted median (OR: 0.97 per SD; 95% CI:

194 0.90-1.05; p-value = 0.52), and weighted mode MR (OR: 0.96 per SD; 95% CI: 0.86-1.08; p-

value = 0.56). The MR-Egger causal estimation produced an OR 1.11 per SD (95% CI: 0.93-

196 1.31; p-value 0.2), the only test to show a direction of effect of increasing COPD causing

- 197 increased risk of Alzheimer's disease. **Figures 5-8** are available in supplementary
- 198 information, demonstrating that results were not driven by an individual SNP. There was no
- evidence of heterogeneity, with a Q-pvalue 0.57.

201 Discussion

202 Evidence before this study

Our results indicate that there is minimal evidence of a causal association between lung 203 function or liability to COPD and risk of Alzheimer's disease. This is in contrast to two large 204 observational studies^(12, 13), which do report an association between COPD and Alzheimer's 205 disease. The observed associations may be due to unmeasured confounding by risk factors 206 207 common to both COPD and Alzheimer's disease such as smoking, physical inactivity, social deprivation and lower educational attainment⁽³⁰⁾. The observational studies may have 208 209 inadvertently included other forms of dementia other than Alzheimer's disease, for example vascular dementia resulting from cerebrovascular or neurological damage. Apolipoprotein e4 210 allele is the biggest risk factor for Alzheimer's disease whereas it is thought that COPD 211 affects cognition via vascular effects. There is evidence that COPD and reduced lung function 212 is associated with micro and macrovascular damage that could mediate the relationship.⁽³¹⁻³³⁾ 213 It is possible that vascular dementia is causally linked to COPD and lung function, but this 214 outcome was not included in our analysis which was restricted to Alzheimer's disease only. 215 Cognitive dysfunction and Mild Cognitive Impairment are well described in COPD ⁽⁶⁾. It may 216 be that this association is causal, but that patients do not progress to Alzheimer's disease due 217 to their lung disease. Survivor bias (where selection is conditional upon survival to 218 recruitment⁽³⁴⁾) can be of concern in studies involving potentially fatal diseases of later life. 219 220 Potentially, patients with COPD would be less likely to be recruited to a GWAS, biasing the MR towards a null. Observational studies performed by analysing health records may be less 221 likely to be affected by this. 222

223 Impact of this study

This analysis uses two-sample MR and multivariable MR to explore a causal association

between lung function, COPD and Alzheimer's disease. The increasing incidence of

Alzheimer's disease in Western society has been described as an epidemic ⁽³⁵⁾. COPD is 226 responsible for 5% of global disability-adjusted life years and 5% of total deaths ⁽³⁶⁾. 227 228 Consequently, prevention and treatment of both COPD and Alzheimer's disease is a global health priority. Although there have been efforts to search for causal mechanisms linking the 229 two diseases, our analysis using multiple means of assessing causation would suggest 230 scientific attention and health prevention resources may be better focused on overlapping risk 231 factors such as smoking, diet and physical activity ^(37, 38), rather than attempts to reduce risk 232 of AD by improving lung function or reducing liability to COPD alone. 233

234

235 <u>Strengths and Limitations</u>

By using randomly assigned genetic variants as an exposure, two-sample MR methodology 236 eliminates many confounders in observational epidemiology $^{(14)}$. We used a large number of 237 robust lung function SNPs, which have been well validated in large samples.^(16, 18) 238 It is important to ensure that the assumptions of MR are met when dealing with SNPs for 239 complex phenotypes like lung function and COPD. We adhered to proposed methodological 240 guidelines of MR (STROBE)⁽³⁹⁾ which are designed to increase reliability of MR reporting. 241 None of the sensitivity tests provided strong evidence for a violation of the MR assumptions. 242 COPD is a binary trait, so our SNPs confer liability to COPD. As this is a Two Sample MR 243 study, we do not know how many participants in the outcome population had COPD. COPD 244 245 is a clinical diagnosis with set spirometric thresholds, whereas in the discovery GWAS a diagnosis of COPD was made based on spirometric criteria alone. This was done by 246 dichotomising continuous traits. Dichotomization of continuous traits in MR studies can 247 make interpretation of the causal estimate less reliable, but MR can still be a valid test of the 248 causal null hypothesis for a binary exposure.⁽⁴⁰⁾ 249

As the SNPs were discovered in populations of those with European ancestry, the results may not be generalisable to other populations. However, we believe the findings of this study are likely to be generalisable to the non-European population as a genetic risk score of the lung function SNPs was validated in other ancestral populations, with slightly reduced effect ⁽¹⁶⁾.

255 <u>Conclusions</u>

Lung function and liability to COPD are not causally associated with an increased risk of

257 Alzheimer's disease. Previous observational studies showing and association between

258 impaired lung function or COPD and Alzheimer's disease are most likely due to unmeasured

confounding.

260

261 Acknowledgements

- We acknowledge participants and investigators of the $IGAP^{(20)}$, $ADSP^{(21)}$, $PGC^{(22)}$,
- 263 UKBiobank and Spirometa groups, and the authors of the Alzheimer's disease⁽²³⁾ lung
- 264 function⁽¹⁶⁾ and COPD⁽¹⁸⁾ GWAS.

265 **References**

- Schwab P, Dhamane AD, Hopson SD, Moretz C, Annavarapu S, Burslem K, Renda A, Kaila S. Impact
 of comorbid conditions in COPD patients on health care resource utilization and costs in a
 predominantly Medicare population. *International journal of chronic obstructive pulmonary disease* 2017; 12: 735-744.
- 2. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. *The European respiratory journal* 2006; 28: 1245-1257.
- 3. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension
 and cardiovascular disease in COPD. *The European respiratory journal* 2008; 32: 962-969.
- 4. Agusti A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later life: a
 transgenerational cohort analysis. *The Lancet Respiratory medicine* 2017; 5: 935-945.
- 5. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. *The European respiratory journal* 2009; 33: 1165-1185.
- 278 6. Dodd JW. Lung disease as a determinant of cognitive decline and dementia. *Alzheimer's research*279 & *therapy* 2015; 7: 32.
- 7. Chang SS, Chen S, McAvay GJ, Tinetti ME. Effect of coexisting chronic obstructive pulmonary
 disease and cognitive impairment on health outcomes in older adults. *Journal of the American Geriatrics Society* 2012; 60: 1839-1846.
- 8. Incalzi RA, Gemma A, Marra C, Capparella O, Fuso L, Carbonin P. Verbal Memory Impairment in
 COPD: Its Mechanisms and Clinical Relevance. *Chest* 1997; 112: 1506-1513.
- 9. Gilsanz P, Mayeda ER, Flatt J, Glymour MM, Quesenberry CP, Jr., Whitmer RA. Early Midlife
 Pulmonary Function and Dementia Risk. *Alzheimer disease and associated disorders* 2018;
 32: 270-275.
- 10. Silva MVF, Loures CdMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MdG. Alzheimer's
 disease: risk factors and potentially protective measures. *J Biomed Sci* 2019; 26: 33-33.
- 11. Incalzi RA, Gemma A, Marra C, Muzzolon R, Capparella O, Carbonin P. Chronic obstructive
 pulmonary disease. An original model of cognitive decline. *The American review of respiratory disease* 1993; 148: 418-424.
- 12. Liao KM, Ho CH, Ko SC, Li CY. Increased Risk of Dementia in Patients With Chronic Obstructive
 Pulmonary Disease. *Medicine* 2015; 94: e930.
- 13. Lutsey PL, Chen N, Mirabelli MC, Lakshminarayan K, Knopman DS, Vossel KA, Gottesman RF,
 Mosley TH, Alonso A. Impaired Lung Function, Lung Disease and Risk of Incident Dementia.
 American journal of respiratory and critical care medicine 2018.
- 14. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in
 epidemiological studies. *Human Molecular Genetics* 2014; 23: R89-R98.
- 300 15. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian
 301 randomization. *Statistical methods in medical research* 2017; 26: 2333-2355.
- 302 16. Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, Batini C, Fawcett
 303 KA, Song K, Sakornsakolpat P, Li X, Boxall R, Reeve NF, Obeidat Me, Zhao JH, Wielscher M,
 304 Weiss S, Kentistou KA, Cook JP, Sun BB, Zhou J, Hui J, Karrasch S, Imboden M, Harris SE,
 305 Marten J, Enroth S, Kerr SM, Surakka I, Vitart V, Lehtimäki T, Allen RJ, Bakke PS, Beaty TH,
 306 Bleecker ER, Bossé Y, Brandsma C-A, Chen Z, Crapo JD, Danesh J, DeMeo DL, Dudbridge F,
- 307 Ewert R, Gieger C, Gulsvik A, Hansell AL, Hao K, Hoffman JD, Hokanson JE, Homuth G, Joshi
- 308 PK, Joubert P, Langenberg C, Li X, Li L, Lin K, Lind L, Locantore N, Luan Ja, Mahajan A,
- 309 Maranville JC, Murray A, Nickle DC, Packer R, Parker MM, Paynton ML, Porteous DJ,
- 310 Prokopenko D, Qiao D, Rawal R, Runz H, Sayers I, Sin DD, Smith BH, Soler Artigas M, Sparrow
- D, Tal-Singer R, Timmers PRHJ, Van den Berge M, Whittaker JC, Woodruff PG, Yerges Armstrong LM, Troyanskaya OG, Raitakari OT, Kähönen M, Polašek O, Gyllensten U, Rudan I,
- 313 Deary IJ, Probst-Hensch NM, Schulz H, James AL, Wilson JF, Stubbe B, Zeggini E, Jarvelin M-R,
- 314 Wareham N, Silverman EK, Hayward C, Morris AP, Butterworth AS, Scott RA, Walters RG,

- Meyers DA, Cho MH, Strachan DP, Hall IP, Tobin MD, Wain LV, Understanding Society
 Scientific G. New genetic signals for lung function highlight pathways and chronic obstructive
 pulmonary disease associations across multiple ancestries. *Nature Genetics* 2019; 51: 481493.
- 17. Wain L, Shrine N, Guyatt A, Jackson V, Erzurumluoglu AM, Batini C, Reeve N, Hobbs B, Cho M,
 Strachan D, Morris A, Hall I, Tobin M. A weighted genetic risk score based on 279 signals of
 association with lung function predicts Chronic Obstructive Pulmonary Disease. *European Respiratory Journal* 2018; 52: OA2188.
- 323 18. Sakornsakolpat P, Prokopenko D, Lamontagne M, Reeve NF, Guyatt AL, Jackson VE, Shrine N, 324 Qiao D, Bartz TM, Kim DK, Lee MK, Latourelle JC, Li X, Morrow JD, Obeidat Me, Wyss AB, 325 Bakke P, Barr RG, Beaty TH, Belinsky SA, Brusselle GG, Crapo JD, de Jong K, DeMeo DL, 326 Fingerlin TE, Gharib SA, Gulsvik A, Hall IP, Hokanson JE, Kim WJ, Lomas DA, London SJ, 327 Meyers DA, O'Connor GT, Rennard SI, Schwartz DA, Sliwinski P, Sparrow D, Strachan DP, Tal-328 Singer R, Tesfaigzi Y, Vestbo J, Vonk JM, Yim J-J, Zhou X, Bossé Y, Manichaikul A, Lahousse L, 329 Silverman EK, Boezen HM, Wain LV, Tobin MD, Hobbs BD, Cho MH, Shrine N, Guyatt AL, 330 Batini C, Zhao JH, Wielscher M, Weiss S, Kentistou KA, Cook JP, Hui J, Karrasch S, Imboden M, 331 Harris SE, Marten J, Enroth S, Kerr SM, Surakka I, Vitart V, Lehtimäki T, Ewert R, Gieger C, 332 Homuth G, Joshi PK, Langenberg C, Lind L, Luan Ja, Mahajan A, Murray A, Porteous DJ, Rawal 333 R, Smith BH, Timmers PRHJ, Raitakari OT, Kähönen M, Polasek O, Gyllensten U, Rudan I, 334 Deary IJ, Probst-Hensch NM, Schulz H, James AL, Wilson JF, Stubbe B, Zeggini E, Jarvelin M-R, 335 Wareham N, Hayward C, Morris AP, Strachan DP, Hall IP, Tobin MD, Wain LV, Agusti A, 336 Anderson W, Bakerly N, Bakke P, Bals R, Barnes KC, Barr RG, Beaty TH, Bleecker ER, Boezen 337 HM, Bossé Y, Bowler R, Brightling C, de Bruijne M, Castaldi PJ, Celli B, Cho MH, Coxson HO, Crapo JD, Crystal R, de Jong P, Dirksen A, Dy J, Foreman M, Garcia-Aymerich J, Gevenois P, 338 339 Ghosh S, Gietema H, Gulsvik A, Hall IP, Hansel N, Hersh CP, Hobbs BD, Hoffman E, Kalsheker 340 N, Kauczor H-U, Kim WJ, Kim DK, Laitinen T, Lambrechts D, Lee S-D, Litonjua AA, Lomas DA, 341 London SJ, Loth DW, Lutz SM, Lynch D, MacNee W, McDonald M-L, Meyers DA, Newell JD, 342 Nordestgaard BG, O'Connor GT, Obeidat Me, Oh Y-M, Paré PD, Pistolesi M, Postma DS, 343 Puhan M, Regan E, Rich SS, Seo JB, Short A, Silverman EK, Sparrow D, Stoel B, Strachan DP, 344 Sverzellati N, Tal-Singer R, ter Riet G, Tesfaigzi Y, Tobin MD, Van Beek EJR, van Ginneken B, 345 Vestbo J, Vogelmeier CF, Wain LV, Wanner A, Washko G, Wauters E, Wouters EFM, Young 346 RP, Zeigler-Heitbrock L, SpiroMeta C, Understanding Society Scientific G, International CGC. 347 Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-348 type and phenotype associations. Nature Genetics 2019; 51: 494-505.

349 19. https://www.ukbiobank.ac.uk/.

350 20. Lambert J-C, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, Jun G, DeStefano AL, 351 Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin C-F, Gerrish A, 352 353 Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau M-T, Choi S-H, Reitz C, Pasquier F, 354 Hollingworth P, Ramirez A, Hanon O, Fitzpatrick AL, Buxbaum JD, Campion D, Crane PK, 355 Baldwin C, Becker T, Gudnason V, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, 356 Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Morón FJ, Rubinsztein DC, 357 Eiriksdottir G, Sleegers K, Goate AM, Fiévet N, Huentelman MJ, Gill M, Brown K, Kamboh MI, 358 Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, 359 Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, 360 Tsuang DW, Yu L, Tsolaki M, Bossù P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia 361 F, Fox NC, Hardy J, Naranjo MCD, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, 362 Matthews F, European Alzheimer's Disease I, Genetic, Environmental Risk in Alzheimer's D, Alzheimer's Disease Genetic C, Cohorts for H, Aging Research in Genomic E, Moebus S, 363 364 Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, 365 Nacmias B, Gilbert JR, Mayhaus M, Lannfelt L, Hakonarson H, Pichler S, Carrasquillo MM,

366 Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson 367 KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, 368 O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley Jr TH, Bennett DA, Harris 369 TB, Fratiglioni L, Holmes C, de Bruijn RFAG, Passmore P, Montine TJ, Bettens K, Rotter JI, 370 Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, 371 Lunetta KL, Kauwe JSK, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER, 372 Schmidt R, Rujescu D, Wang L-S, Dartigues J-F, Mayeux R, Tzourio C, Hofman A, Nöthen MM, 373 Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, 374 Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, 375 Schellenberg GD, Amouyel P. Meta-analysis of 74,046 individuals identifies 11 new 376 susceptibility loci for Alzheimer's disease. Nature Genetics 2013; 45: 1452. 377 21. dbGaP. Genotypes and Phenotypes. [cited 2019. Available from: 378 https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000572.v7.p4. 379 22. Medicine USo. 2019. Available from: https://www.med.unc.edu/pgc/pgc-380 workgroups/alzheimers-disease-workgroup/. 381 23. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hägg 382 S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, Stringer S, Aarsland D, Almdahl IS, Andersen F, 383 Bergh S, Bettella F, Bjornsson S, Brækhus A, Bråthen G, de Leeuw C, Desikan RS, Djurovic S, 384 Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kiddle SJ, Rongve A, Saltvedt I, Sando SB, 385 Selbæk G, Shoai M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, White LR, Hardy J, 386 Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson R, Davis LK, Stefansson H, Stefansson K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D. Genome-wide meta-analysis identifies 387 388 new loci and functional pathways influencing Alzheimer's disease risk. Nature Genetics 2019; 389 51: 404-413. 390 24. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, 391 Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM, 392 Davey Smith G, Gaunt TR, Haycock PC. The MR-Base platform supports systematic causal 393 inference across the human phenome. eLife 2018; 7. 394 25. Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in Mendelian 395 randomization studies. International journal of epidemiology 2011; 40: 755-764. 396 26. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-forgotten) 397 practices: the design, analysis, and interpretation of Mendelian randomization studies. Am J 398 Clin Nutr 2016; 103: 965-978. 399 27. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely 400 measured traits using GWAS summary data. PLoS genetics 2017; 13: e1007081. 401 28. Daborg J, von Otter M, Sjölander A, Nilsson S, Minthon L, Gustafson DR, Skoog I, Blennow K, 402 Zetterberg H. Association of the RAGE G82S polymorphism with Alzheimer's disease. Journal 403 of neural transmission (Vienna, Austria: 1996) 2010; 117: 861-867. 404 29. Jansen H, Lieb W, Schunkert HJCD, Therapy. Mendelian Randomization for the Identification of 405 Causal Pathways in Atherosclerotic Vascular Disease. 2016; 30: 41-49. 406 30. Crous-Bou M, Minguillón C, Gramunt N, Molinuevo JL. Alzheimer's disease prevention: from risk 407 factors to early intervention. Alzheimer's research & therapy 2017; 9: 71-71. 408 31. McKay GJ, McCarter RV, Hogg RE, Higbee DH, Bajaj MK, Burrage DR, Ruickbie S, Baker EH, Jones 409 PW, Dodd JW. Simple non-mydriatic retinal photography is feasible and demonstrates retinal 410 microvascular dilation in Chronic Obstructive Pulmonary Disease (COPD). PloS one 2020; 15: 411 e0227175. 412 32. Liao D, Higgins M, Bryan NR, Eigenbrodt ML, Chambless LE, Lamar V, Burke GL, Heiss G. Lower 413 pulmonary function and cerebral subclinical abnormalities detected by MRI: the 414 Atherosclerosis Risk in Communities study. Chest 1999; 116: 150-156.

- 33. Dodd JW, Chung AW, van den Broek MD, Barrick TR, Charlton RA, Jones PW. Brain structure and
 function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance
 imaging study. *American journal of respiratory and critical care medicine* 2012; 186: 240-245.
- 418 34. Vansteelandt S, Dukes O, Martinussen T. Survivor bias in Mendelian randomization analysis.
 419 *Biostatistics* 2017; 19: 426-443.
- 35. Johnson N, Davis T, Bosanquet N. The Epidemic of Alzheimer's Disease. *PharmacoEconomics* 2000; 18: 215-223.
- 422 36. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, 423 Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, 424 Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak 425 A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, 426 Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, 427 Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross 428 M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des 429 Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, 430 Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman 431 MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, 432 Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, 433 Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton 434 LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, 435 Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, 436 Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, 437 Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, 438 Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, 439 Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, 440 Perico N, Phillips D, Pierce K, Pope CA, 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, 441 Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, 442 Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, 443 Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, 444 Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang 445 M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, 446 Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and 447 regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a
- 448 systematic analysis for the Global Burden of Disease Study 2010. *Lancet (London, England)*449 2012; 380: 2095-2128.
- 37. Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, Zhao QF, Li JQ, Wang J, Yu JT. Meta-analysis of
 modifiable risk factors for Alzheimer's disease. *Journal of neurology, neurosurgery, and psychiatry* 2015; 86: 1299-1306.
- 38. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive
 pulmonary disease. *The Lancet* 2015; 385: 899-909.
- 39. Davey Smith G DN, Dimou N, Egger M, Gallo V, Golub R, Higgins JP, Langenberg C, Loder EW,
 Richards JB, Richmond RC, Skrivankova VW, Swanson SA, Timpson NJ, Tybjaerg-Hansen A,
 VanderWeele TJ, Woolf BA, Yarmolinsky J. STROBE-MR: Guidelines for strengthening the
 reporting of Mendelian randomization studies. *PeerJ Preprints* 2019; 7:e27857v1.
- 459 40. Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable:
 460 interpretation and presentation of causal estimates. *Eur J Epidemiol* 2018; 33: 947-952.
- 461
- 462
- 463

Figure 1. Scatter plot of the SNP-effect on lung function trait and SNP-effect on Alzheimer's disease

Each point on the graph represents the SNP-outcome association plotted against the SNPexposure association. Bars indicate 95% confidence intervals. Coloured lines represent analysis method used. This shows no effect of lung function on Alzheimer's disease . MR Egger intercept is close to zero indicating no unbalanced directional pleiotropy.



Figure 2. Single SNP analysis of lung function traits on Alzheimer's disease

Each point represents individual SNP calculated effect size for lung function on the odds of Alzheimer's disease. Bars indicate 95% CI.



Figure 3. Leave-one-out analysis of lung function traits on Alzheimer's disease

Each point represents the IVW estimate if the SNP on the y axis was left out of total analysis. Bars indicate 95% confidence intervals, demostrating that no individual SNP is driving the causal effect estimate.



Figure 4. Funnel plot of heterogeneity of causal effects of lung function traits on

Alzheimer's disease

Each point is a SNP with its beta plotted against its inverse standard error. As the graph is funnel shaped, it indicates no heterogeneity.



Online Data Supplement

Examining the possible causal relationship between Lung Function, COPD and Alzheimer's Disease. A Mendelian Randomization Study

Daniel H Higbee, Raquel Granell, Esther Walton, Roxanna Korologou-Linden, George Davey Smith, James W Dodd

Contents

Appendix 1. Figures for COPD specific SNPs

Appendix 2. Assumptions and tests

Appendix 3. Details of sample populations

Appendix 4. Flow chart of analyses

Appendix 5. Data and code availability

Appendix 1. Figures for COPD SNPs

Figure E1. Scatter Plot of IVW COPD and AD

Each point on the graph represents the SNP-outcome association plotted against the SNPexposure association. Bars indicate 95% confidence intervals. Coloured lines represent analysis method used. This shows no significant effect of COPD on Alzheimer's disease . MR Egger intercept is close to zero indicating no unbalanced directional pleiotropy.



Figure E2. Single SNP Analysis of COPD and AD

Each point represents individual SNP calculated effect size for COPD on odds of

Alzheimer's disease . Bars indicate 95% CI.



Figure E3. Leave one out analysis of COPD and AD

Each point represents the IVW estimate if the SNP on the y axis was left out of total analysis. Bars indicate 95% confidence intervals. It demostrates that no individual SNP is driving the causal effect estimate.



Figure E4. Funnel Plot analysis of COPD and AD

Each point is a SNP with its beta plotted against its inverse standard error. As the graph is funnel shaped, it indicates no heterogeneity.



Appendix 2

Assumptions

We assume that our IVs have a true association with the exposures. This has been rigorously statistically tested in the discovery GWAS and effect estimation ^(1, 2). F-statistic calculation shows that all exposure SNPs were unlikely to be weak instruments. In both GWAS papers SNPs discovered are related to specific genes, cell types and biological pathways for lung tissue development.

We assume that our SNPs do not affect AD except via their effect on LF/COPD, and that the SNPs have no associations with any confounders that are also associated with AD. Although not possible to directly tests, our sensitivity and heterogeneity tests reduce the risk these assumptions were violated. To account for the possibility of horizontal pleiotropy (IVs affect multiple pathways) we performed MR Egger, weighted median and weighted mode tests. MR-Egger is similar to IVW except the y intercept is unconstrained. If the y intercept of the MR-Egger is not equal to zero then either there is unbalanced horizontal pleiotropy (the average pleiotropic effect differs from zero) or the pleiotropic effects are independent from the genetic association with the risk factor, or both ⁽³⁾. Although power is lower compared to IVW, the gradient of the MR-Egger gives a causal estimate of the dose-response relationship between the genetic associations with the risk factor and those with the outcome, providing additional evidence for causal affect. To help avoid the effect of unbalanced instruments on an overall estimate of the mean by the IVW method, weighted median and mode MR methods were performed. A weighted median MR gives a consistent estimate of the causal effect when at least 50% of the weight comes from valid IVs, giving a greater robustness with strongly outlying causal estimates ⁽⁴⁾. A weighted mode MR calculates an estimate based on the set of SNPs that form the largest homogenous cluster, which attempts to avoid the impact of invalid instruments ⁽⁵⁾.

There was no evidence of population stratification (when subgroups within a sample are of different genetic ancestry) as assessed by linkage disequilibrium score regression in the original GWAS.

Steiger Filtering

Steiger filtering estimates each SNP's rsq.exposure and rsq.outcome in the outcome population.⁽⁶⁾ Those SNPs that explain more variance in the outcome than exposure are excluded, as they could led to a reverse causal relationship. SNPs were removed if they explained more variance of the outcome than the exposure. SNPs were removed if they explained more variance of the outcome than the exposure. Necessary information to perform Steiger filtering includes knowing the case and control numbers for each SNP. In our main Alzheimer's meta-analysis outcome population, we only know this for the PGC cohort. Therefore, we assumed that for the SNPs tested for in the ADSP and IGAP cohorts, every SNP had the same case and control number as the overall participant numbers. For ADSP 4,343 cases and 3,165 controls, for IGAP 17,008 cases and 14,471 controls. A prevalence of the outcome as required for Steiger filtering, we stated that the prevalence of the outcome was 0.07. Similarly, we do not know the exact case and control number for each SNP in the COPD exposure. Therefore, we assumed that every SNP had the same case and control number as the total number of case (35,735) and control (222,076) participants in the study. We estimated the prevalence to be 0.1 as per the discovery GWAS. Lung function is a continuous trait, so does not require estimation of prevalence to perform Steiger filtering.

Appendix 3. Details of Sample Populations

Table E1. Description of GWAS samples used

Exposure	Data source (PMID)	Sample size (% cases)	% European	GWAS Adjustment
Lung function	UKBiobank & SpiroMeta	400,102	100	age, age ² , sex, height, smoking status
COPD	25 studies*	257,811 (13.8%)	100	age, age ² , sex, and height
Outcome	Data source (PMID)	Sample size (% cases)	% European	GWAS Adjustment
Alzheimer's Disease	IGAP, ADSP, PGC	79,865 (31%)	100	ADSP&PGC = gender, batch, 4 principal components PGC = age

*Please see supplementary table 1 of reference⁽²⁾ for full table naming each study with

description of respective: cases/controls number, smoking status, age, FEV1% and FEV1/FVC

Appendix 4. Flow chart of analysis

Study protocols were not pre-registered.

Figure E5. Flow chart of analysis for all lung function trait SNPs⁽¹⁾



Figure E6. Flow chart of analysis for FEV1 SNPs



Figure E7. Flow Chart of analysis for FVC SNP's



Figure E8. Flow Chart of analysis for effect FEV₁/FVC SNPs



Figure E9. Flow Chart of analysis for COPD liability SNPs⁽²⁾



Appendix 5

Code available on request from corresponding author.

Data used was summary data freely available in supplementary tables or from corresponding authors of GWAS.

References

1. Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nature Genetics. 2019;51(3):481-93.

2. Sakornsakolpat P, Prokopenko D, Lamontagne M, Reeve NF, Guyatt AL, Jackson VE, et al. Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nature Genetics. 2019;51(3):494-505.

3. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. International journal of epidemiology. 2015;44(2):512-25.

4. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. 2016;40(4):304-14.

5. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. Human Molecular Genetics. 2018;27(R2):R195-R208.

6. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS genetics. 2017;13(11):e1007081.